07.01.2017 Fresenius Medical Care AG & Co. KGaA  DE0005785802

DGAP-Adhoc: Fresenius Medical Care AG & Co. KGaA: Impact of potential regulation change


 
DGAP-Ad-hoc: Fresenius Medical Care AG & Co. KGaA / Key word(s): Statement Fresenius Medical Care AG & Co. KGaA: Impact of potential regulation change 07-Jan-2017 / 02:31 CET/CEST Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Fresenius Medical Care: Impact of potential regulation change Centers for Medicare and Medicaid Services (CMS) promulgated a new regulation regarding premium assistance programs that help to fund health insurance premiums for patients with end stage renal disease (ESRD). Many financially needy Americans receive grants from nonprofit charities to help them obtain health insurance. For decades, the American Kidney Fund (AKF) has provided such premium assistance to ESRD patients. The new regulation, which is scheduled to become effective on January 13, 2017, threatens to put an end to premium assistance for certain ESRD patients. The regulation, should it become effective, and the continuing efforts by insurers - through their discussions with CMS and otherwise - to reject premium assistance for ESRD patients, may result in a material adverse effect on our business. Between 700 and 2,000 FMCNA ESRD patients who currently use premium assistance in connection with individual market plans on and off the exchanges may be impacted by the regulation and/or continuing insurer efforts to reject premium assistance. Fresenius Medical Care Holdings, Inc. (FMCNA) has joined other providers and patient advocates in filing a lawsuit challenging the rulemaking process and stop the regulation to become effective. On January 3, 2017, FMCNA accepted service of a subpoena from the United States Attorney for the District of Massachusetts calling for the production of information related to the premium assistance program operated by the AKF. FMCNA is cooperating with this investigation. --------------------------------------------------------------------------- 07-Jan-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Fresenius Medical Care AG & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg Germany Phone: +49 (0) 6172- 609 2525 Fax: +49 (0) 6172- 609 2301 E-mail: [email protected] Internet: www.freseniusmedicalcare.com ISIN: DE0005785802, , WKN: 578580, 578583 Indices: DAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; NYSE End of Announcement DGAP News Service --------------------------------------------------------------------------- 534707 07-Jan-2017 CET/CEST


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 17.784,00 16.547,00 17.476,56 17.859,06 17.618,69 19.398,02 19.453,62
EBITDA1,2 3.098,00 3.763,00 3.862,72 4.090,31 3.475,97 3.350,00 3.121,41
EBITDA-Marge3 17,42 22,74 22,10 22,90 19,73 17,27
EBIT1,4 2.362,00 3.038,00 2.269,56 2.304,41 1.852,29 1.511,76 1.369,44
EBIT-Marge5 13,28 18,36 12,99 12,90 10,51 7,79 7,04
Jahresüberschuss1 1.554,00 2.226,00 1.438,50 1.435,83 1.219,03 894,33 732,46
Netto-Marge6 8,74 13,45 8,23 8,04 6,92 4,61 3,77
Cashflow1,7 2.192,00 2.062,00 2.566,95 4.233,16 2.489,50 2.167,38 2.628,80
Ergebnis je Aktie8 4,17 6,47 3,96 3,96 3,31 2,30 1,70
Dividende8 1,06 1,17 1,20 1,34 1,35 1,12 0,96
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

INVESTOR-INFORMATIONEN
©boersengefluester.de
Fresenius Medical Care
WKN Kurs in € Einschätzung Börsenwert in Mio. €
578580 35,600 Halten 10.445,52
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
12,49 17,80 0,69 10,03
KBV KCV KUV EV/EBITDA
0,79 3,97 0,54 5,64
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
1,12 1,19 3,34 16.05.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
07.05.2024 30.07.2024 05.11.2024 22.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-2,38% -9,23% -6,22% -7,00%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Fresenius Medical Care AG & Co. KGaA  ISIN: DE0005785802 können Sie bei EQS abrufen


Medtech , 578580 , FME , XETR:FME